Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Minimal0–2
- Mild3–6
- Moderate7–12
- Severe13–18
The Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale calculator is designed for bedside assessing disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms in clinical practice. The resulting score directly guides.
Clinical Guidelines & Evidence
Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.
Clinical Indication
The Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale is indicated for bedside clinical practice to support Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Widely used in clinical trials and routine clinical practice for monitoring disease severity and treatment response.
MG-ADL Total Score = Talking + Chewing + Swallowing + Breathing + Brushing teeth/combing hair + Rising from chair + Eyelid droop + Double vision (each item scored 0-3)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| talking | integer | Yes | Difficulty with speech due to muscle weakness affecting vocal cords and mouth muscles |
| chewing | integer | Yes | Difficulty with chewing due to weakness of masticatory muscles |
| swallowing | integer | Yes | Difficulty with swallowing due to weakness of pharyngeal and esophageal muscles |
| breathing | integer | Yes | Respiratory muscle weakness affecting breathing function |
| brushing_teeth_combing_hair | integer | Yes | Difficulty with arm elevation and sustained muscle activity for personal care |
| rising_from_chair | integer | Yes | Difficulty rising from seated position due to proximal leg muscle weakness |
| eyelid_droop | integer | Yes | Ptosis - drooping of upper eyelids due to weakness of levator palpebrae muscles |
| double_vision | integer | Yes | Diplopia - double vision due to weakness of extraocular muscles |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Minimal | Minimal functional impairment |
| 3–6 | Mild | Mild functional impairment |
| 7–12 | Moderate | Moderate functional impairment |
| 13–18 | Severe | Severe functional impairment |
| 19–24 | Very Severe | Very severe functional impairment |
Evidence-Based References (EBM)
- Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.DOI: 10.1212/wnl.52.7.1487
- Muppidi S, Wolfe GI, Conaway M, Burns TM; MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31. doi: 10.1002/mus.22140.DOI: 10.1002/mus.22140
- Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434-40. doi: 10.1212/WNL.0b013e3181dc1b1e.DOI: 10.1212/WNL.0b013e3181dc1b1e